Literature DB >> 11839584

DeltaN-p73alpha accumulates in human neuroblastic tumors.

Sétha Douc-Rasy1, Michel Barrois, Maria Echeynne, Mourad Kaghad, Etienne Blanc, Gilda Raguenez, David Goldschneider, Marie-José Terrier-Lacombe, Olivier Hartmann, Ute Moll, Daniel Caput, Jean Bénard.   

Abstract

Neuroblastic tumors (NTs), occurring in early childhood, display a wide spectrum of differentiation. Recurrent deletions involving the p73 locus are frequently observed in undifferentiated NTs. To address the question of the possible implication of p73 in neuroblastic differentiation, we investigated the status of the expression of this gene in a panel of differentiated and undifferentiated tumors. Although mutations were not found, p73 transcript profiles differed between undifferentiated and differentiated tumors. The frequency of the transcripts lacking exon 2 (species 1-3) appeared to be higher in undifferentiated than in differentiating and differentiated NTs. In contrast, products from using an alternate promoter (DeltaN-p73) were present in all NTs. In addition, only DeltaN-p73, but not full-length proteins, were detected by immunoblotting, suggesting a greater stability of N-truncated isoforms. Importantly, as in the adrenal medulla, most NTs showed p73-positive immunohistological staining with a cellular distribution and intensity varying according to the neuronal differentiation. Surprisingly, we observed redistribution of p73 from the nucleus to the cytoplasm during neuroblastic differentiation. Our data suggest that, in undifferentiated NTs, a link may exist between the accumulation of DeltaN-p73alpha variants and the "nuclear exclusion" of p53.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839584      PMCID: PMC1850642          DOI: 10.1016/s0002-9440(10)64883-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Mdm2 binds p73 alpha without targeting degradation.

Authors:  E Bálint; S Bates; K H Vousden
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

2.  Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.

Authors:  A E Sayan; B S Sayan; N Findikli; M Ozturk
Journal:  Oncogene       Date:  2001-08-23       Impact factor: 9.867

3.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

4.  Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells.

Authors:  N Sidell; H P Koeffler
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

5.  Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53.

Authors:  I Fillippovich; N Sorokina; M Gatei; Y Haupt; K Hobson; E Moallem; K Spring; M Mould; M A McGuckin; M F Lavin; K K Khanna
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

6.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours.

Authors:  A Yang; N Walker; R Bronson; M Kaghad; M Oosterwegel; J Bonnin; C Vagner; H Bonnet; P Dikkes; A Sharpe; F McKeon; D Caput
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

7.  An anti-apoptotic role for the p53 family member, p73, during developmental neuron death.

Authors:  C D Pozniak; S Radinovic; A Yang; F McKeon; D R Kaplan; F D Miller
Journal:  Science       Date:  2000-07-14       Impact factor: 47.728

8.  Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif.

Authors:  A Minty; X Dumont; M Kaghad; D Caput
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

9.  A proposed staging for children with neuroblastoma. Children's cancer study group A.

Authors:  A E Evans; G J D'Angio; J Randolph
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

Review 10.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

View more
  12 in total

Review 1.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

Review 2.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

3.  p73 in Cancer.

Authors:  Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight
Journal:  Genes Cancer       Date:  2011-04

4.  Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and ∆Np73 in medulloblastoma cell lines.

Authors:  Marta Nekulová; Karel Zitterbart; Jaroslav Sterba; Renata Veselská
Journal:  J Mol Histol       Date:  2010-08-28       Impact factor: 2.611

5.  Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness.

Authors:  Roman A Blaheta; Wolf-Dietrich Beecken; Tobias Engl; Dietger Jonas; Elsie Oppermann; Michael Hundemer; Hans Wilhelm Doerr; Martin Scholz; Jindrich Cinatl
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

6.  BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD).

Authors:  Y Niikura; H Ogi; K Kikuchi; K Kitagawa
Journal:  Cell Death Differ       Date:  2010-01-08       Impact factor: 15.828

7.  Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.

Authors:  Thilakavathy Thangasamy; Sivanandane Sittadjody; Geoffrey C Mitchell; Erin E Mendoza; Vijayababu M Radhakrishnan; Kirsten H Limesand; Randy Burd
Journal:  BMC Cancer       Date:  2010-06-11       Impact factor: 4.430

Review 8.  Mechanisms, function and clinical applications of DNp73.

Authors:  Cuixia Di; Lina Yang; Hong Zhang; Xiaofei Ma; Xin Zhang; Chao Sun; Hongyan Li; Shuai Xu; Lizhe An; Xun Li; Zhongtian Bai
Journal:  Cell Cycle       Date:  2013-06-13       Impact factor: 4.534

9.  deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.

Authors:  Oleksi Petrenko; Alexander Zaika; Ute M Moll
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

10.  N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.

Authors:  A R M Ruhul Amin; V S Thakur; K Gupta; M K Agarwal; D N Wald; D M Shin; M L Agarwal
Journal:  Oncogene       Date:  2012-03-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.